Immune responses to the HLA-A*0201-restricted epitopes of tyrosinase and glycoprotein 100 enable control of melanoma outgrowth in HLA-A*0201-transgenic mice

Journal of Immunology

Volumn 167, Issue 9, 2001, Pages 4853-4860

  Mullins, D W ^a   Bullock, T N J ^a   Colella, T A ^a   Robila, V V ^a   Engelhard, V H ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 100; HLA A ANTIGEN; MONOPHENOL MONOOXYGENASE; RECOMBINANT ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; HLA SYSTEM; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MELANOCYTE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 0035501024     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.9.4853     Document Type: Article

References (66)

1. Vaccination for malignant melanoma: Recent developments
2. Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma
3. The future of interleukin-2: Enhancing therapeutic anticancer vaccines
4. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
5. Mutated mitogen-activated protein kinase: A tumor rejection antigen of mouse sarcoma
6. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies
7. Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2
8. Efficient identification of novel HLA-A*0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis
9. Identification of HLA-A2-restricted epitopes of the tumor-associated antigen MUC2 recognized by human cytotoxic T cells
10. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use
11. Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA-A2.1
12. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
13. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins
14. + NK cells
15. 2IL-4, and IL-10 is responsible for UV-induced systemic immune suppression
16. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines
17. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes
18. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression
19. Recombinant interleukin-12 suppresses the synthesis of immunoglobulin E by interleukin-4 stimulated human lymphocytes
20. Retroviral vectors for use in human gene therapy for cancer, Gaucher disease, and arthritis
21. + cytotoxic T lymphocytes
22. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes
23. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy
24. Identification of tumor-regression antigens in melanoma
25. + T lymphocytes
26. Adenovirusmediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma
27. Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the ELISPOT assay
28. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides
29. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
30. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
31. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma
32. Immunopotentiating role of IFN-γ in early and late stages of type 1 CD8 effector cell-mediated tumor rejection
33. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: A murine tumor model
34. Tumor antigens are constitutively presented in the draining lymph nodes
35. - T cells
36. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose
37. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model
38. Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells
39. Species specificity in the interaction of CD8 with the α3 domain of MHC class I molecules
40. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1
41. The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice
42. Selftolerance to the murine homologue of a tyrosinase-derived melanoma antigen. Implications for tumor immunotherapy
43. Molecular analysis of radiation-induced albino (c)-locus mutations that cause death at preimplantation stages of development
44. Impairment of the melanogenic pathway in B 16 melanoma cells transfected with class I H-2 genes
45. Association of human class I MHC alleles with the adenovirus E3/19K protein
46. Importance of MHC class I α2 and α3 domains in the recognition of self and non-self MHC molecules
47. The monoclonal antibody CR11-351 discriminates HLA-A2 variants identified by T cells
48. Partial purification and some properties of BB7.2: A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28
49. Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo
50. Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization
51. Tyrosinase expression and melanogenesis in melanotic and amelanotic B16 mouse melanoma cells
52. A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12
53. + cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo
54. Melanomas with concordant loss of multiple melanocytic differentiation proteins: Immune escape that may be overcome by targeting unique or undefined antigens
55. Immune selection after antigen-specific immunotherapy of melanoma
56. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides
57. Improved induction of melanomareactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A *0201 -binding residues
58. gp100/ pmel 17 is a murine tumor rejection antigen: Induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand
59. An autologous oral DNA vaccine protects against murine melanoma
60. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy
61. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma
62. Antigen-specific Inhibition of effector T cell function in humans after injection of immature dendritic cells
63. Differentiation of T regulatory cells by immature dendritic cells
64. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex
65. Alterations in TCR-MHC contacts subsequent to cross-recognition of class I MHC and singly substituted peptide variants
66. + T cells in melanoma immunotherapy in human MHC class I transgenic mice